EMM Journal Submission Guide 2026

Don't waste months in review if your paper doesn't match EMM's scope. Here's how to know in 5 minutes:

• Submit if your paper has:

• Mechanistic studies using molecular approaches

• Translational research connecting bench findings to clinical relevance

• Disease models with therapeutic implications

• Biomarker discovery with validation data

• Don't submit if you have:

• Pure clinical studies without molecular components

• Bioinformatics-only analyses without experimental validation

• Basic cell culture work without disease connection

• Single-method papers without broader biological context

EMM competes directly with journals like Molecular Medicine, Disease Models & Mechanisms, and Laboratory Investigation. If your work fits multiple categories, EMM typically offers faster review times than higher-impact alternatives but requires stronger translational angles than basic science journals.

The editors filter on scope during initial screening: the guide for authors says papers judged to be of insufficient general interest or otherwise inappropriate are rejected promptly without external review. EMM does not publish a desk-rejection rate.

Experimental and Molecular Medicine publishes research that bridges molecular mechanisms with medical applications. The journal's scope statement welcomes basic discoveries with clinical relevance and articles dealing with clear in vivo relevance and novelty.

• Priority research areas include:

• Cancer biology with therapeutic targets

• Metabolic disorders and diabetes research

• Cardiovascular disease mechanisms

• Neurological and neurodegenerative diseases

• Inflammatory and autoimmune conditions

• Genetics and genomics, gene therapy, and stem cells and regenerative medicine

• Article types accepted:

• Articles (original research; 6,000 words max excluding the abstract, tables, figure legends and references; up to 8 display items)

• Reviews (6,000 words max; up to 8 display items)

• Correspondences (typically 250 to 500 words, no more than 10 references)

• Solicited Editorials (1,500 words, 20 references)

The guide for authors lists no case-report article type, and its scope statement centers on experimental and translational research performed with specific molecular tools, so plan for wet lab data combined with clinical relevance.

• What separates accepted papers from rejected ones: Strong papers typically include multiple experimental approaches. A typical accepted cancer paper might combine cell culture studies, animal models, and analysis of patient samples. The editors want to see progression from molecular mechanism to biological significance.

Weak submissions often focus too narrowly on single pathways or use only one experimental system. Papers that describe interesting biology without connecting to disease get rejected during peer review, even if they pass initial screening.

The journal particularly values papers that identify new therapeutic targets or biomarkers. If your work suggests a druggable pathway or diagnostic application, emphasize this connection throughout your manuscript.

Recent issues show increasing acceptance of papers using CRISPR, organoid models, and single-cell sequencing technologies. Traditional approaches still get published, but novel methodologies catch editor attention during initial screening.

• Geographic and institutional considerations: EMM publishes work from global institutions, but many papers come from Asian research groups, particularly Korea, China, and Japan. This reflects both the journal's origins and the editorial board composition. International collaborations appear frequently in higher-impact papers.

EMM operates on a standard academic timeline with some publisher-specific variations.

• Published timing (journal information page, read 2026-10-09):

• Median time from submission to first editorial decision: 29 days

• Median time from submission to acceptance: 161 days

• The journal does not publish stage-by-stage timing, a desk-rejection rate or a revision deadline.

Papers that pass initial screening typically go to 2 referees, according to the journal's referee page; the guide for authors says two or more independent reviewers. Referee identities are not released to authors unless a referee asks to be identified.

Most papers that clear editorial triage still require revision, and the process is usually more iterative than authors expect. Papers with major revisions can still succeed, but only if the translational logic and experimental support hold up under closer review.

Queries about a submitted manuscript go to the editorial office listed on the journal's contact page.

Most desk rejections happen for predictable reasons. Avoid these specific errors:

• Scope mismatch problems:

• Submitting pure bioinformatics work without wet lab validation

• Clinical studies without molecular mechanism components

• Basic biology papers without disease connection

• Method development without biological application

• Technical formatting issues:

• Missing ethics approval statements for animal or human studies

• Incomplete author contribution statements

• Figures in wrong file format or resolution

• Reference formatting that doesn't match journal style

• Cover letter mistakes:

• Generic letters that could apply to any journal

• Failing to explain clinical relevance

• Overselling results with promotional language

• Not addressing potential scope concerns

• Common manuscript problems:

• Results presented without statistical analysis

• Methods sections missing critical protocol details

• Discussion that doesn't address study limitations

• Figures that are illegible or poorly labeled

EMM editors particularly dislike papers that bury their main finding in dense results sections. Lead with your strongest data and clearest biological interpretation.

Another frequent issue: papers that describe interesting biology but don't explain why it matters for human health. Even basic mechanism studies need clear connections to disease processes or therapeutic potential.

The fastest way to desk rejection is submitting work that's clearly outside EMM's experimental medicine focus. When editors see pure computational studies or clinical observations without mechanistic data, the guide for authors says papers judged inappropriate for the journal are rejected promptly without external review.

This page covers the published rules. The draft still needs testing against this specific journal. The review tells you whether your paper clears the EMM Journal fit check before upload, especially around bioinformatics or computational analysis without wet lab validation, translational framing without clinical data or patient samples, and scope confusion between basic biology and experimental medicine. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

For manuscripts targeting Experimental and Molecular Medicine, three recurring patterns explain the majority of desk rejections among the papers we analyze.

In our pre-submission review work, we see many desk rejections at Experimental and Molecular Medicine trace to scope or framing problems that prevent the paper from competing in this venue. We also often find these cases involve insufficient methodological rigor or missing validation evidence. A related pattern is that these cases often arise from a novelty claim that outpaces the supporting data.

Each pattern below is a desk-rejection risk we see in EMM-targeted manuscripts, and addressing these before submission reduces early-rejection risk.

Bioinformatics or computational analysis without wet lab validation

EMM's scope statement centers on experimental and translational research performed with specific molecular tools. We see a consistent pattern of submissions where the computational pipeline is sophisticated but the validation is either absent or limited to one cell line without disease-model context. Editors flag this at desk review because the journal's entire scope is built around experimental medicine with molecular biology grounding. A transcriptomic analysis of disease samples needs at least one validation experiment connecting the finding to a functional mechanism.

Check bioinformatics or computational analysis without wet lab validation before submitting to EMM Journal →

Translational framing without clinical data or patient samples

EMM prioritizes work connecting molecular mechanisms to disease understanding, and we observe that papers claiming therapeutic implications based solely on cell culture data, without animal models or patient sample analysis, are increasingly desk-rejected. The journal's scope statement emphasizes clinical benefit for human health, so the screening question is whether this finding can plausibly translate to the clinic. A cancer biology paper with three cell lines and no in vivo data or clinical correlation will face consistent scrutiny unless the mechanistic novelty is exceptional.

Check translational framing without clinical data or patient samples before submitting to EMM Journal →

Scope confusion between basic biology and experimental medicine

We find that papers describing interesting biology without connecting to disease processes are rejected at EMM even when the science is strong. A study identifying a new protein interaction or signaling pathway is a basic science paper; an EMM paper needs to explain why that interaction drives pathology in a specific disease context. The distinction is whether the manuscript is telling a biology story or a disease story. EMM wants the disease story.

Clarivate 2026 JCR release bibliometric data provides additional benchmarks when evaluating journal fit.

SciRev collects unofficial author-reported review times; the journal's own median from submission to first editorial decision is 29 days across all submissions (journal information page, read 2026-10-09). A EMM submission readiness check can identify whether your translational evidence and experimental validation meet EMM's editorial standard before you upload.

Check scope confusion between basic biology and experimental medicine before submitting to EMM Journal →

For EMM-targeted manuscripts, three patterns consistently predict desk-screen failure at Experimental & Molecular Medicine (Springer Nature, Korean Society for Biochemistry). The patterns below are the ones we see most often at first-pass triage.

Scope-fit ambiguity in the abstract

EMM editors move fastest on manuscripts whose contribution is obviously aligned with molecular medicine research with mechanistic depth and translational pathway. The named failure pattern: mechanism-only papers without clinical-translation pathway extend revision rounds. Check whether your abstract reads to EMM's scope

Methods package incomplete for the journal's reviewer pool

EMM reviewers expect specific methodological detail. Clinical observational studies without mechanistic underpinning extend reviewer consultation. Check if your methods package is reviewer-complete

Reference-list and clean-citation failure mode

A reference list that cites retracted papers is an avoidable risk, and the guide for authors says authors are responsible for the accuracy of the references. Check whether your reference list is clean against Crossref + Retraction Watch

Editorial evidence signal for Experimental & Molecular Medicine (Springer Nature, Korean Society for Biochemistry)

Our review of public author guidance, recent published article packages, and Manusights pre-submission review patterns points to this practical risk: Emm reviewers expect both molecular-mechanism depth and explicit clinical-translation pathway; mechanism-only or clinical-only papers extend revision. Treat this as a fit-and-artifact screen rather than a private outcome claim; official journal pages remain authoritative for submission mechanics and policy requirements.

• For manuscript preparation: Journal Cover Letter Template: 5 Filled-In Examples for Any Journal (2026) offers specific templates and common mistakes to avoid.

• Before you submit anywhere: How to Choose the Right Journal for Your Paper (A Practical Guide) helps you compare EMM with similar journals in experimental medicine.

• If your paper isn't ready: 10 Signs Your Paper Isn't Ready to Submit (Yet) covers the most common gaps that lead to rejection.

Need an expert review before submission? Manusights provides detailed manuscript assessments that identify scope issues and technical problems before they reach journal editors.

Tracking a paper that is already with the journal? The Experimental & Molecular Medicine Under Review status guide breaks down what each status label signals and how long it usually holds.

Getting the venue right saves more time than getting the formatting right. Check my abstract's scope fit against Experimental and Molecular Medicine before I reformat.